Investors

Overview

Corporate Profile

Gamida Cell is an advanced cell therapy company committed to finding cures for patients with cancer and other serious diseases. We harness our NAM-enabled technology platform to create therapies with the potential to improve the course of cancer care.

Data Provided by Refinitiv. Minimum 15 minutes delayed.

Latest News

View All
Oct 19, 2021

Gamida Cell to Present at Society for Immunotherapy of Cancer's (SITC) 36th Annual Meeting

Read More
Sep 28, 2021

Gamida Cell to Host Virtual Event Highlighting GDA-201 and NAM-Enabled, Genetically Modified NK Cell Therapy Pipeline

Read More
Sep 02, 2021

Gamida Cell to Present Corporate Highlights at Multiple Investor Conferences in September

Read More
Aug 11, 2021

Gamida Cell Reports Second Quarter 2021 Financial Results and Provides Company Update

Read More
Aug 04, 2021

Gamida Cell Announces the Date of Its Second Quarter 2021 Financial Results and Webcast

Read More
Aug 03, 2021

Gamida Cell to Present at the BTIG Virtual Biotechnology Conference

Read More
Jun 23, 2021

Gamida Cell Announces Publication in Blood, the Journal of the American Society of Hematology, of the First Pivotal Trial to Evaluate a Cell Therapy (Omidubicel) for Patients with Blood Cancer who Require an Allogeneic Stem Cell Transplant

Read More
Jun 09, 2021

Gamida Cell to Present Corporate Highlights at Multiple Investor Conferences in June

Read More
Jun 07, 2021

Gamida Cell Announces Appointment of Senior Vice President, Global Operations and Manufacturing and Provides Commercial Manufacturing Update

Read More
May 12, 2021

Gamida Cell to Present at the RBC Capital Markets Global Healthcare Conference

Read More
May 11, 2021

Gamida Cell Reports First Quarter 2021 Financial Results and Provides Company Update

Read More
May 04, 2021

Gamida Cell Announces the Date of Its First Quarter 2021 Financial Results and Webcast

Read More
Apr 07, 2021

Gamida Cell to Present at the 20th Annual Needham Virtual Healthcare Conference

Read More
Mar 15, 2021

Gamida Cell Presents Efficacy and Safety Results of Phase 3 Study of Omidubicel in Patients with Hematologic Malignancies at the 47th Annual Meeting of the European Society for Blood and Marrow Transplantation (EBMT)

Read More
Mar 09, 2021

Gamida Cell Reports Full Year 2020 Financial Results and Provides Company Update

Read More
Mar 03, 2021

Gamida Cell to Present at Upcoming Investor Conferences

Read More
Mar 02, 2021

Gamida Cell Announces the Date of Its Full Year 2020 Financial Results and Webcast

Read More
Mar 01, 2021

Gamida Cell Announces Results from Phase 3 Study of Omidubicel to be Presented at the 47th Annual Meeting of the European Society for Blood and Marrow Transplantation (EBMT)

Read More
Feb 16, 2021

Gamida Cell Announces $75 Million Financing with Highbridge Capital Management

Read More
Feb 09, 2021

Gamida Cell Presents Efficacy and Safety Results of Phase 3 Study of Omidubicel in Patients with Hematologic Malignancies at the 2021 TCT Meetings of ASTCT and CIBMTR

Read More
Corporate Fact Sheet
Corporate Presentation

Investor & Media Contact

Josh Hamermesh
Chief Business Officer
Gamida Cell Ltd.
IRPR@gamida-cell.com